These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26794822)

  • 21. Age- and sex-tailored serum phosphate thresholds do not improve cardiovascular risk estimation in CKD.
    Ferraro PM; Bonello M; Gambaro A; Sturniolo A; Gambaro G
    J Nephrol; 2011; 24(4):446-52. PubMed ID: 21607913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
    Dhillon-Jhattu S; Sprague SM
    Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1-2 Chronic Kidney Disease.
    Saxena A; Sachan T; Gupta A; Kapoor V
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plant phosphates, phytate and pathological calcifications in chronic kidney disease.
    Buades Fuster JM; Sanchís Cortés P; Perelló Bestard J; Grases Freixedas F
    Nefrologia; 2017; 37(1):20-28. PubMed ID: 27697413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperphosphatemia. The hidden killer in chronic kidney disease.
    Askar AM
    Saudi Med J; 2015 Jan; 36(1):13-9. PubMed ID: 25629999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dietary phosphorus, serum phosphorus, and cardiovascular disease.
    Menon MC; Ix JH
    Ann N Y Acad Sci; 2013 Oct; 1301():21-6. PubMed ID: 24117725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phosphate metabolism and nutritional therapy in predialysis patients].
    Hamada Y; Usami M
    Clin Calcium; 2012 Oct; 22(10):1577-82. PubMed ID: 23023639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphate-a poison for humans?
    Komaba H; Fukagawa M
    Kidney Int; 2016 Oct; 90(4):753-63. PubMed ID: 27282935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of Awareness of Dietary Sources of Phosphorus Is a Clinical Concern.
    Shimada M; Shutto-Uchita Y; Yamabe H
    In Vivo; 2019; 33(1):11-16. PubMed ID: 30587596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.
    Wolf M
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1875-85. PubMed ID: 26350436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study.
    McGovern AP; de Lusignan S; van Vlymen J; Liyanage H; Tomson CR; Gallagher H; Rafiq M; Jones S
    PLoS One; 2013; 8(9):e74996. PubMed ID: 24040373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease.
    Felsenfeld AJ; Levine BS; Rodriguez M
    Semin Dial; 2015; 28(6):564-77. PubMed ID: 26303319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.
    Six I; Maizel J; Barreto FC; Rangrez AY; Dupont S; Slama M; Tribouilloy C; Choukroun G; Mazière JC; Bode-Boeger S; Kielstein JT; Drüeke TB; Massy ZA
    Cardiovasc Res; 2012 Oct; 96(1):130-9. PubMed ID: 22822101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.